Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Net Income (2016 - 2025)

Historic Net Income for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$65.2 million.

  • Ocular Therapeutix's Net Income fell 3313.13% to -$65.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$263.5 million, marking a year-over-year decrease of 5962.16%. This contributed to the annual value of -$263.5 million for FY2025, which is 5962.16% down from last year.
  • Ocular Therapeutix's Net Income amounted to -$65.2 million in Q4 2025, which was down 3313.13% from -$68.0 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Net Income ranged from a high of -$19.5 million in Q1 2022 and a low of -$68.0 million during Q3 2025
  • In the last 5 years, Ocular Therapeutix's Net Income had a median value of -$22.9 million in 2022 and averaged -$34.4 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Net Income skyrocketed by 1094.77% in 2022, and later plummeted by 11550.88% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Net Income stood at -$19.7 million in 2021, then dropped by 5.38% to -$20.8 million in 2022, then decreased by 9.42% to -$22.7 million in 2023, then plummeted by 115.51% to -$49.0 million in 2024, then tumbled by 33.13% to -$65.2 million in 2025.
  • Its Net Income was -$65.2 million in Q4 2025, compared to -$68.0 million in Q3 2025 and -$67.2 million in Q2 2025.